NASDAQ / ETF
Defiance Autism Impact ETF
ASD
Market price
$26.38
Source / date
Yahoo Finance chart · 10/2/2026, 8:00:00 PM
Exchange-traded prices may be delayed or unavailable from the quote provider. Company P/E-based scores, DCF valuation and forensic analysis do not apply to this listing; the analysis below uses the framework appropriate to its investment type.
DeepScreen investment analysis
ETF basket analysis
Refreshed 10/3/2026, 3:21:35 AM
Basket and structure
What the ETF owns and how the reported portfolio is classified.
- Benchmark / index
- Health
- Fund family
- Defiance ETFs LLC
- Provider listing name
- Defiance Autism Impact ETF
- Legal structure
- Exchange Traded Fund
- Inception
- 2026-06-01
- First recorded trade
- 2026-06-02
Market listing label; not a verified fund-family disclosure.
Provider's first available trade, not necessarily fund launch.
Price history
Returns and risk calculated from available adjusted-price history, not a benchmark comparison.
- 52-week high
- $28.52
- 52-week low
- $24.59
Holding quality and valuation
Weighted fundamentals are calculated only across holdings for which usable company fundamentals are available.
- Weighted ROE
- 4.11%
- Weighted earnings growth
- -4.61%
- Weighted debt / equity
- 0.45
32.4% of reported weight covered.
Risk and concentration
Portfolio concentration plus realized and provider-published risk statistics.
- Top-10 weight
- 32.4%
- Largest sector
- healthcare · 87.9%
- Top-3 sector weight
- 95.1%
- 3Y max drawdown
- -6.68%
- 5Y max drawdown
- -6.68%
- 3Y volatility
- 18.4%
- Beta
- 0
Cost and execution
Ownership cost, tracking quality and exchange-trading friction where the source publishes them.
- Expense ratio / TER
- 0.79%
- Bid / ask spread
- 56.211%
- Premium / discount to NAV
- 0.284%
- AUM
- $1.38M
- Average volume
- 449
- Latest session volume
- 324
Not an average.
Top reported holdings
| Holding | Symbol | Weight |
|---|---|---|
| Definium Therapeutics Inc Ordinary Shares | DFTX | 3.95% |
| Neuren Pharmaceuticals Ltd | NEU.AX | 3.65% |
| LifeStance Health Group Inc Ordinary Shares | LFST | 3.44% |
| Otsuka Holdings Co Ltd | 4578.T | 3.34% |
| Repligen Corp | RGEN | 3.26% |
| ACADIA Pharmaceuticals Inc | ACAD | 3.24% |
| Revvity Inc | RVTY | 3.04% |
| Life Healthcare Group Holdings Ltd | LHC.JO | 2.86% |
| Bristol-Myers Squibb Co | BMY | 2.81% |
| BioMarin Pharmaceutical Inc | BMRN | 2.81% |
DeepScreen displays verified values returned by its current sources. Metrics without a verified value are omitted rather than shown as empty placeholder cards.
Investment FAQ
Questions about Defiance Autism Impact ETF
Research answers for Defiance Autism Impact ETF (ASD) using the analysis framework appropriate to a ETF.
ETF FAQ
- What is Defiance Autism Impact ETF (ASD)?
- Defiance Autism Impact ETF is listed by DeepScreen as an exchange-traded fund. An ETF represents a portfolio of underlying assets while its units trade on an exchange during market hours. Research the fund's benchmark or strategy, holdings, concentration, costs, tracking quality and trading liquidity rather than evaluating it as a single operating company.
- How should I analyze Defiance Autism Impact ETF?
- Analyze Defiance Autism Impact ETF as a basket. Check what index or strategy it follows, the weight of its largest holdings and sectors, portfolio valuation and quality where meaningful, historical drawdown and volatility, expense ratio, tracking difference, tracking error, bid-ask spread, AUM, volume and premium or discount to NAV.
- What tracking metrics matter for Defiance Autism Impact ETF?
- For a benchmark-tracking ETF, compare both tracking difference and tracking error. Tracking difference shows how far the fund's return has lagged or exceeded its benchmark over a period, while tracking error measures how variable that gap has been. Fees, cash holdings, rebalancing and implementation costs can affect both.
- Is Defiance Autism Impact ETF a good ETF to buy?
- DeepScreen does not provide a personalized buy recommendation. Assess whether Defiance Autism Impact ETF's benchmark or strategy, concentration, costs, tracking, liquidity and risk fit the exposure you are researching, and verify the issuer's latest factsheet and prospectus before making an investment decision.